Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 256.26M | 249.38M | 246.46M | 243.29M | 248.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 256.26M | 249.38M | 246.46M | 243.29M | 248.91M |
| Cost of Revenue | 132.59M | 128.75M | 132.51M | 130.14M | 133.73M |
| Gross Profit | 123.68M | 120.63M | 113.95M | 113.15M | 115.18M |
| SG&A Expenses | 68.33M | 66.79M | 64.63M | 62.05M | 66.36M |
| Depreciation & Amortization | 32.96M | 33.32M | 33.19M | 33.38M | 37.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 248.72M | 243.49M | 243.94M | 238.58M | 250.87M |
| Operating Income | 7.54M | 5.89M | 2.52M | 4.72M | -1.96M |
| Income Before Tax | -23.55M | -17.37M | -17.73M | -16.09M | -13.91M |
| Income Tax Expenses | -945.40K | -1.84M | -5.00M | -3.81M | -8.33M |
| Earnings from Continuing Operations | -22.61 | -15.52 | -12.73 | -12.27 | -5.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.61M | -15.52M | -12.73M | -12.27M | -5.58M |
| EBIT | 7.54M | 5.89M | 2.52M | 4.72M | -1.96M |
| EBITDA | 42.16M | 40.90M | 36.96M | 39.50M | 38.47M |
| EPS Basic | -0.22 | -0.15 | -0.13 | -0.12 | -0.04 |
| Normalized Basic EPS | -0.06 | -0.03 | -0.02 | -0.02 | 0.02 |
| EPS Diluted | -0.22 | -0.16 | -0.13 | -0.13 | -0.05 |
| Normalized Diluted EPS | -0.06 | -0.03 | -0.02 | -0.02 | 0.02 |
| Average Basic Shares Outstanding | 407.35M | 412.47M | 419.62M | 429.96M | 443.08M |
| Average Diluted Shares Outstanding | 407.35M | 412.73M | 420.08M | 430.43M | 443.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
